NasdaqGM:NRIXBiotechs
A Look At Nurix Therapeutics (NRIX) Valuation As DAYBreak Phase 2 Trial Progresses
Nurix Therapeutics (NRIX) has kicked off its DAYBreak registrational Phase 2 trial for bexobrutideg in relapsed or refractory chronic lymphocytic leukemia after reaching regulatory agreement on dosing, following encouraging Phase 1 efficacy and durability data.
See our latest analysis for Nurix Therapeutics.
The DAYBreak launch comes after a strong 90 day share price return of about 40%, even though the 1 year total shareholder return is a loss of around 9%. This suggests recent momentum has...